Hospitals awaiting regulator's guidance over Ranbaxy drugs

RanbaxyRanbaxy was asked to pay $500 mn to settle US govt charges of selling adulterated drugs. (Reuters)

Leading hospitals in Mumbai are awaiting guidance from the regulator Food and Drug Administration before taking any decision on issuing advisory over prescribing drugs manufactured by Ranbaxy.

"FDA is the regulatory authority here and unless it tells us, we will not do anything ... (issue advisory) over prescribing Ranbaxy drugs," Hinduja Hospital Director

Professional Services Dr Gustad Daver said.

Earlier, Jaslok Hospital in Mumbai had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.

Apollo Pharmacy, India's largest pharmacy chain, has also issued 'cautionary' advisory based on concerns raised by the medical committee last week.

Leading hospitals in Mumbai like Kokilaben Hospital, KEM Hospital, Nanavati and Bombay Hospital have continued to prescribe the Ranbaxy drugs.

On May 13, Ranbaxy was asked to pay USD 500 million to settle the US government charges of selling adulterated drugs manufactured at its two plants in India.

The Indian Medical Association has asked the Drug Controller General of India to investigate the quality of drugs manufactured and sold by Ranbaxy.

Ranbaxy Laboratories is an integrated international pharmaceuticals company engaged in the marketing, production and distribution of pharmaceuticals products.

It manufactures medicines for cardiovascular, respiratory and gastro-intestinal ailments, besides anti-retroviral drugs.

Please read our terms of use before posting comments
TERMS OF USE: The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
comments powered by Disqus